Lixte Biotechnology Holdings, Inc. (LIXT)
| Market Cap | 28.59M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -5.97M |
| Shares Out | 13.75M |
| EPS (ttm) | -0.49 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 31,398 |
| Open | 2.09 |
| Previous Close | 2.07 |
| Day's Range | 2.06 - 2.11 |
| 52-Week Range | 1.97 - 7.19 |
| Beta | -1.35 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings Date | n/a |
About LIXT
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically ac...
Financial Performance
Financial StatementsNews
Lixte Biotechnology's LB-100 Shown in Animal Models to Significantly Reduce Behavioral Sensitization, an Important Fe...
A series of recent pre - clinical reports demonstrat e s LB-100's effectiveness in various non - neoplastic diseases that may benefit from PP2A inhibition
Best Biotech Penny Stocks For Your Small-Caps Watchlist Right Now
Biotech penny stocks are heating up right now; here's 3 to watch The post Best Biotech Penny Stocks For Your Small-Caps Watchlist Right Now appeared first on Penny Stocks to Buy, Picks, News and Informa...
Lixte Biotechnology Shares Are Trading Higher On Encouraging Preclinical LB-100 Data In Lung Cancer
Lixte Biotechnology Holdings Inc (NASDAQ: LIXT) has announced that its lead compound, LB-100, a protein phosphatase 2A (PP2A) inhibitor, was reported to enhance the effectiveness of elements of standard...
LIXTE BIOTECHNOLOGY'S LB-100 ELICITS ANTI- TUMOR ACTIVITY IN SMALL LUNG CANCER MODELS BY UNIQUE MECHANISMS IN AN IMPO...
A Pre-Clinical Study Reports that LB -100 Potentiates Standard Therapy f or Small Cell Lung Cancer Providing a Strong Rational e f or a Clinical Trial o f LB -100 i n Small Cell Lung Cancer Recently Ini...
LIXTE BIOTECHNOLOGY COMMENTS ON REPORT THAT ITS PP2A INHIBITOR LB-100 COMBINED WITH ANOTHER INVESTIGATIONAL AGENT STI...
Altadena, CA, July 22, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq:LIXTE) a clinical-stage drug discovery company developing pharmacologically active drugs for improving cancer t...
Lixte Biotechnology Comments on Outside Research Citing LB-100's PP2A Inhibition as a Potential Therapeutic Strategy ...
Altadena, CA, July 13, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. ( Nasdaq: LIXT) (“Lixte” or the “Company”) noted that Julio Pimentel, a fourth-year doctoral student in the Wayne State...
Lixte Biotechnology to Present its Drug Development Pipeline for Cancer Treatment at The MoneyShow Virtual Expo on Ju...
Presentation to highlight Company's current clinical stud y of lead compound LB-100 for Small Cell Lung Cancer
Lixte Biotechnology and City of Hope Enroll First Patient in Phase 1b Trial of Lead Compound LB-100 for Treatment of ...
EAST SETAUKET, NY, June 02, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cance...
LIXTE BIOTECHNOLOGY HOLDINGS, INC. ANNOUNCES THE APPOINTMENT OF REGINA BROWN TO ITS BOARD OF DIRECTORS
EAST SETAUKET, NY, May 12, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq : LIXT) today announced the appointment of Regina Brown, CPA to its board of directors. She will serve as a...
Lixte Biotechnology to Present Key Advantages of Novel Cancer Drug Candidate LB-100 at the Sidoti Virtual Microcap Co...
Multiple pre-clinical studies indicate that Lixte's lead clinical drug candidate LB-100 enhances the effectiveness of many standard anticancer treatments
Lixte Biotechnology Holdings, Inc. Announces the Appointment of Gil N Schwartzberg to its Board of Directors
EAST SETAUKET, New York, April 13, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (“Lixte” or the “Company”) ( Nasdaq: LIXT ), a clinical-stage drug discovery company developing pharmacolog...
Lixte Biotechnology to Showcase Its Anti-Cancer Therapy Enhancer LB-100 at the Virtual 33rd Annual ROTH Capital Confe...
EAST SETAUKET, NY, March 03, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc . (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in can...
WestPark Capital Announces Completion of $4.19 Million Registered Direct Offering for Lixte Biotechnology Holdings, I...
LOS ANGELES--(BUSINESS WIRE)--WestPark Capital, Inc., a full-service investment bank and securities broker-dealer, today announced the completion of a Registered Direct Offering for Lixte Biotechnology ...
WallachBeth Capital Announces Completion of $4.19 Million Registered Direct Offering for Lixte Biotechnology Holdings...
JERSEY CITY, N.J., March 2, 2021 /PRNewswire/ -- WallachBeth Capital, a leading provider of capital markets and institutional execution services, announced the completion of a Registered Direct Offering...
Lixte Biotechnology Announces the Closing of $4.19 Million Registered Direct Offering
East Setauket, March 02, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer t...
Why Morphic, Athenex, Lixte Biotech Are Moving Today
Morphic Holding Inc (NASDAQ: MORF), Athenex Inc (NASDAQ: ATNX) and Lixte Biotechnology Holdings Inc (NASDAQ: LIXT) are among the healthcare movers on Monday. Morphic Jumps On Data: Morphic, a biopharma ...
Lixte Biotechnology Announces $4.19 Million Registered Direct Offering
East Setauket, March 01, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. ( Nasdaq: LIXT ), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer...
LIXT Stock: 8 Things to Know About Lixte Biotechnology As Shares Blast Off
Lixte Biotechnology (LIXT) stock is heading higher on Friday with heavy trading of shares despite a lack of news concerning the company. The post LIXT Stock: 8 Things to Know About Lixte Biotechnology A...
Lixte Biotechnology to Present Its Anti-Cancer Therapy Enhancer LB-100 at the Virtual H.C. Wainwright Global Life Sci...
EAST SETAUKET, NY, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc . (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in canc...
Lixte Biotechnology and City of Hope to Initiate Phase 1b Clinical Trial of Lixte's Lead Compound LB-100 to Treat Sma...
EAST SETAUKET, NY, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc . (NASDAQ: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in canc...